Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;8(3):566-571.
doi: 10.21037/jgo.2017.02.02.

Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer

Tetsuhito Muranaka  1   2 , Masaki Kuwatani  1 , Yoshito Komatsu  2 , Kentaro Sawada  1 , Hiroshi Nakatsumi  2 , Yasuyuki Kawamoto  2 , Satoshi Yuki  1 , Yoshimasa Kubota  3 , Kimitoshi Kubo  4 , Shuhei Kawahata  5 , Kazumichi Kawakubo  1 , Hiroshi Kawakami  3 , Naoya Sakamoto  1
Affiliations

Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer

Tetsuhito Muranaka et al. J Gastrointest Oncol. 2017 Jun.

Abstract

Background: Irinotecan, oxaliplatin and leucovorin-modulated fluorouracil (FOLFIRINOX) and the combination regimen of gemcitabine and nanoparticle albumin-bound paclitaxel (GnP) (nab-PTX) improve the prognosis of patients with metastatic pancreatic cancer. However, no study has compared the efficacy of the two regimens. We compared retrospectively the efficacy and safety of the two regimens in patients with unresectable pancreatic cancer.

Methods: Thirty-eight patients with unresectable locally advanced or metastatic pancreatic cancer received FOLFIRINOX or GnP as first-line chemotherapy between December 2013 and September 2015. In the FOLFIRINOX group, patients received 85 mg/m2 oxaliplatin followed by 180 mg/m2 irinotecan and 200 mg/m2 L-leucovorin, and by 400 mg/m2 fluorouracil as a bolus and 2,400 mg/m2 fluorouracil as a 46-h continuous infusion every 14 days. In the GnP group, patients received 125 mg/m2 nab-PTX followed by 1 g/m2, and gemcitabine on days 1, 8 and 15, repeated every 28 days.

Results: Response rate was 6.3% in the FOLFIRINOX group and 40.9% in the GnP group (P=0.025). Median progression-free survival (PFS) was 3.7 months [95% confidence interval (CI), 3.0-4.5] in the FOLFIRINOX group and 6.5 months (95% CI, 6.2-6.9 months) in the GnP group (P=0.031). Drug toxicity in the GnP group was less than in the FOLFIRINOX group.

Conclusions: Efficacy and safety of GnP compare favorably to those of FOLFIRINOX in patients with pancreatic cancer. Additional prospective trials are warranted.

Keywords: FOLFIRINOX; Pancreatic cancer; albumin-bound paclitaxel; chemotherapy; gemcitabine; paclitaxel.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Y Komatsu received honoraria from Taiho Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry Co. Ltd., Daiichi Sankyo Ltd. and Bristol-Myers Squibb. N Sakamoto received honoraria from Bristol-Myers Squibb, MSD, Gilead Sciences, and Otuka. The other authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Figures

Figure 1
Figure 1
Median PFS was 3.7 months (95% CI, 3.0–4.5 months) in the FOLFIRINOX group versus 6.5 months (95% CI, 6.2–6.9 months) in the GnP group (HR, 0.41; 95% CI, 0.18–0.95; P=0.031). PFS, progression-free survival; CI, confidence interval; FOLFIRINOX, irinotecan, oxaliplatin and leucovorin-modulated fluorouracil; GnP, gemcitabine and nanoparticle albumin-bound paclitaxel.
Figure 2
Figure 2
Median overall survival was 9.9 months (95% CI, 5.9–13.9 months) in the FOLFIRINOX group and not reached in the GnP group. CI, confidence interval; FOLFIRINOX, irinotecan, oxaliplatin and leucovorin-modulated fluorouracil; GnP, gemcitabine and nanoparticle albumin-bound paclitaxel.
See this image and copyright information in PMC

References

    1. Conroy T, Bachet JB, Ayav A, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer 2016;57:10-22. 10.1016/j.ejca.2015.12.026 - DOI - PubMed
    1. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. 10.1200/JCO.1997.15.6.2403 - DOI - PubMed
    1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. 10.1056/NEJMoa1011923 - DOI - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. 10.1056/NEJMoa1304369 - DOI - PMC - PubMed
    1. Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci 2014;105:1321-6 10.1111/cas.12501 - DOI - PMC - PubMed